{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T20:40:14Z","timestamp":1794256814575,"version":"4.9.0"},"reference-count":69,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Annals of Otorhinolaryngology, Head and Neck Diseases"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.anorl.2023.11.004","type":"journal-article","created":{"date-parts":[[2023,11,30]],"date-time":"2023-11-30T15:34:30Z","timestamp":1701358470000},"page":"280-285","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Systemic therapies for salivary gland carcinoma (excluding adenoid cystic carcinoma): REFCOR recommendations by the formal consensus method"],"prefix":"10.1016","volume":"141","author":[{"given":"V.","family":"Sarradin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Digue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Vergez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Thariat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Fakhry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Chabrillac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.-J.","family":"Bensadoun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.-R.","family":"Ferrand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Even","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.anorl.2023.11.004_bib0350","doi-asserted-by":"crossref","first-page":"100602","DOI":"10.1016\/j.esmoop.2022.100602","article-title":"Salivary gland cancer: ESMO\u00a0\u2013\u00a0European Reference Network on Rare Adult Solid Cancers (EURACAN) clinical practice guideline for diagnosis, treatment and follow-up","volume":"7","author":"van Herpen","year":"2022","journal-title":"ESMO Open"},{"key":"10.1016\/j.anorl.2023.11.004_bib0355","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.anorl.2023.11.012","article-title":"Salivary gland cancer: Recommendations by formal consensus, for the French Network of Rare Head and Neck Tumors (REFCOR)","volume":"141","author":"Vergez","year":"2024","journal-title":"Eur Ann Otorhinolaryngol Head Neck Dis"},{"key":"10.1016\/j.anorl.2023.11.004_bib0360","doi-asserted-by":"crossref","DOI":"10.1016\/j.anorl.2023.11.009","article-title":"Systemic therapies for salivary gland cancer: Adenoid cystic carcinoma. REFCOR recommendations by the formal consensus method","author":"Ferrand","year":"2024","journal-title":"Eur Ann Otorhinolaryngol Head Neck Dis"},{"key":"10.1016\/j.anorl.2023.11.004_bib0365","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1016\/j.annonc.2020.03.304","article-title":"Gastroenteropancreatic neuroendocrine neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"31","author":"Pavel","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.anorl.2023.11.004_bib0370","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.anorl.2023.11.005","article-title":"Surgery of major salivary gland cancers: REFCOR recommendations by the formal consensus method","volume":"41","author":"Barry","year":"2024","journal-title":"Eur Ann Otorhinolaryngol Head Neck Dis"},{"key":"10.1016\/j.anorl.2023.11.004_bib0375","doi-asserted-by":"crossref","DOI":"10.1016\/j.anorl.2023.11.011","article-title":"Surgery of sublingual and minor salivary gland cancer: REFCOR recommendations by the formal consensus method","author":"Pham Dang","year":"2024","journal-title":"Eur Ann Otorhinolaryngol Head Neck Dis"},{"key":"10.1016\/j.anorl.2023.11.004_bib0380","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.anorl.2023.11.001","article-title":"Lymph node surgery for salivary gland cancer: REFCOR recommendations by the formal consensus method","volume":"141","author":"Baujat","year":"2024","journal-title":"Eur Ann Otorhinolaryngol Head Neck Dis"},{"key":"10.1016\/j.anorl.2023.11.004_bib0385","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.anorl.2023.11.006","article-title":"Radiotherapy for salivary gland cancer: REFCOR recommendations by the formal consensus method","volume":"141","author":"Thariat","year":"2024","journal-title":"Eur Ann Otorhinolaryngol Head Neck Dis"},{"key":"10.1016\/j.anorl.2023.11.004_bib0390","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.anorl.2023.11.002","article-title":"Cytopathological analysis of salivary gland cancer: REFCOR recommendations by the formal consensus method","volume":"141","author":"Courtade-Sa\u00efdi","year":"2024","journal-title":"Eur Ann Otorhinolaryngol Head Neck Dis"},{"key":"10.1016\/j.anorl.2023.11.004_bib0395","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.annpat.2014.01.006","article-title":"Pathologists and the French network of expertise on rare cancers ENT: the REFCORpath","volume":"34","author":"Badoual","year":"2014","journal-title":"Ann Pathol"},{"key":"10.1016\/j.anorl.2023.11.004_bib0400","doi-asserted-by":"crossref","first-page":"101906","DOI":"10.1016\/j.ctrv.2019.101906","article-title":"Advances and challenges in precision medicine in salivary gland cancer","volume":"80","author":"Lassche","year":"2019","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.anorl.2023.11.004_bib0405","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1097\/CCO.0000000000000527","article-title":"New approaches in salivary gland carcinoma","volume":"31","author":"Even","year":"2019","journal-title":"Curr Opin Oncol"},{"key":"10.1016\/j.anorl.2023.11.004_bib0410","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1002\/1097-0142(20010201)91:3<541::AID-CNCR1032>3.0.CO;2-Y","article-title":"Phase II randomized trial comparing vinorelbine versus vinorelbine plus cisplatin in patients with recurrent salivary gland malignancies","volume":"91","author":"Airoldi","year":"2001","journal-title":"Cancer"},{"key":"10.1016\/j.anorl.2023.11.004_bib0415","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1002\/hed.20327","article-title":"Phase II trial of taxol in salivary gland malignancies (E1394): a trial of the Eastern Cooperative Oncology Group","volume":"28","author":"Gilbert","year":"2006","journal-title":"Head Neck"},{"key":"10.1016\/j.anorl.2023.11.004_bib0420","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/S1470-2045(10)70245-X","article-title":"Systemic therapy in the management of metastatic or locally recurrent adenoid cystic carcinoma of the salivary glands: a systematic review","volume":"12","author":"Laurie","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.anorl.2023.11.004_bib0425","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1002\/hed.10034","article-title":"Response to paclitaxel and carboplatin in metastatic salivary gland cancer: a case report","volume":"24","author":"Ruzich","year":"2002","journal-title":"Head Neck"},{"key":"10.1016\/j.anorl.2023.11.004_bib0430","first-page":"3781","article-title":"Paclitaxel and carboplatin for recurrent salivary gland malignancies","volume":"20","author":"Airoldi","year":"2000","journal-title":"Anticancer Res"},{"key":"10.1016\/j.anorl.2023.11.004_bib0435","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1177\/019459988609500206","article-title":"Chemotherapy for salivary gland cancer","volume":"95","author":"Kaplan","year":"1986","journal-title":"Otolaryngol Head Neck Surg"},{"key":"10.1016\/j.anorl.2023.11.004_bib0440","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1093\/oxfordjournals.annonc.a010684","article-title":"Cisplatin, doxorubicin and cyclophosphamide in advanced salivary gland carcinoma. A phase II trial of 22 patients","volume":"7","author":"Licitra","year":"1996","journal-title":"Ann Oncol"},{"key":"10.1016\/j.anorl.2023.11.004_bib0445","doi-asserted-by":"crossref","first-page":"2869","DOI":"10.1002\/1097-0142(19871215)60:12<2869::AID-CNCR2820601203>3.0.CO;2-Y","article-title":"Cyclophosphamide, doxorubicin, and cisplatin combination chemotherapy for advanced carcinomas of salivary gland origin","volume":"60","author":"Dreyfuss","year":"1987","journal-title":"Cancer"},{"key":"10.1016\/j.anorl.2023.11.004_bib0450","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1002\/1097-0142(19881201)62:11<2313::AID-CNCR2820621110>3.0.CO;2-4","article-title":"Cisplatin-based chemotherapy for neoplasms arising from salivary glands and contiguous structures in the head and neck","volume":"62","author":"Creagan","year":"1988","journal-title":"Cancer"},{"key":"10.1016\/j.anorl.2023.11.004_bib0455","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1002\/mpo.2950160309","article-title":"Preliminary experience with chemotherapy in advanced salivary gland neoplasms","volume":"16","author":"Belani","year":"1988","journal-title":"Med Pediatr Oncol"},{"key":"10.1016\/j.anorl.2023.11.004_bib0460","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1002\/1097-0142(19810215)47:4<645::AID-CNCR2820470404>3.0.CO;2-A","article-title":"Adriamycin\/cis-platinum\/cyclophosphamide combination chemotherapy for advanced carcinoma of the parotid gland","volume":"47","author":"Alberts","year":"1981","journal-title":"Cancer"},{"key":"10.1016\/j.anorl.2023.11.004_bib0465","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1007\/BF01195348","article-title":"Chemotherapy for recurrent adeno- and adenoidcystic carcinomas in the head and neck","volume":"119","author":"Tsukuda","year":"1993","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.anorl.2023.11.004_bib0470","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1200\/JCO.1990.8.6.1056","article-title":"Fluorouracil, doxorubicin, cyclophosphamide, and cisplatin combination chemotherapy in advanced or recurrent salivary gland carcinoma","volume":"8","author":"Dimery","year":"1990","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.anorl.2023.11.004_bib0475","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1177\/030089168907500312","article-title":"Cisplatin, epirubicin and 5-fluorouracil combination chemotherapy for recurrent carcinoma of the salivary gland","volume":"75","author":"Airoldi","year":"1989","journal-title":"Tumori"},{"key":"10.1016\/j.anorl.2023.11.004_bib0480","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1200\/JCO.1987.5.6.951","article-title":"Cisplatin, doxorubicin, and 5-fluorouracil chemotherapy for salivary gland malignancies: a pilot study of the Northern California Oncology Group","volume":"5","author":"Venook","year":"1987","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.anorl.2023.11.004_bib0485","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.clon.2003.12.001","article-title":"Adenocarcinoma of the salivary gland? A chemo-sensitive disease","volume":"16","author":"White","year":"2004","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"10.1016\/j.anorl.2023.11.004_bib0490","first-page":"47","article-title":"[Efficacy of the combination of 5 fluorouracil, adriamycin and cisplatin (FAP protocol) in the treatment of metastatic cylindroma. Apropos of a case with review of the literature]","volume":"81","author":"Farhat","year":"1994","journal-title":"Bull Cancer"},{"key":"10.1016\/j.anorl.2023.11.004_bib0495","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1097\/00001813-200206000-00007","article-title":"Mitoxantrone and cisplatin in recurrent and\/or metastatic salivary gland malignancies","volume":"13","author":"Gedlicka","year":"2002","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.anorl.2023.11.004_bib0500","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S0964-1955(97)00026-2","article-title":"Cisplatin and 5-fluorouracil for symptom control in advanced salivary adenoid cystic carcinoma","volume":"33","author":"Hill","year":"1997","journal-title":"Oral Oncol"},{"key":"10.1016\/j.anorl.2023.11.004_bib0505","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1002\/cncr.24745","article-title":"A phase 2 study of platinum and gemcitabine in patients with advanced salivary gland cancer: a trial of the NCIC Clinical Trials Group","volume":"116","author":"Laurie","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.anorl.2023.11.004_bib0510","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1002\/1097-0142(19821201)50:11<2261::AID-CNCR2820501105>3.0.CO;2-E","article-title":"Chemotherapy of advanced salivary gland neoplasms","volume":"50","author":"Posner","year":"1982","journal-title":"Cancer"},{"key":"10.1016\/j.anorl.2023.11.004_bib0515","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1002\/hed.2880140403","article-title":"Cisplatin-based chemotherapy in advanced adenoid cystic carcinoma of the head and neck","volume":"14","author":"de Haan","year":"1992","journal-title":"Head Neck"},{"key":"10.1016\/j.anorl.2023.11.004_bib0520","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1002\/1097-0142(19911101)68:9<1874::AID-CNCR2820680904>3.0.CO;2-S","article-title":"Cisplatin in advanced salivary gland carcinoma. A phase II study of 25 patients","volume":"68","author":"Licitra","year":"1991","journal-title":"Cancer"},{"key":"10.1016\/j.anorl.2023.11.004_bib0525","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/BF00216934","article-title":"Southwest Oncology Group study of mitoxantrone for treatment of patients with advanced adenoid cystic carcinoma of the head and neck","volume":"8","author":"Mattox","year":"1990","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.anorl.2023.11.004_bib0530","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1093\/oxfordjournals.annonc.a010770","article-title":"Phase II study on mitoxantrone in adenoid cystic carcinomas of the head and neck. EORTC Head and Neck Cancer Cooperative Group","volume":"7","author":"Verweij","year":"1996","journal-title":"Ann Oncol"},{"key":"10.1016\/j.anorl.2023.11.004_bib0535","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1093\/oxfordjournals.annonc.a058665","article-title":"Epirubicin in patients with advanced or recurrent adenoid cystic carcinoma of the head and neck: a phase II study of the EORTC Head and Neck Cancer Cooperative Group","volume":"4","author":"Vermorken","year":"1993","journal-title":"Ann Oncol"},{"key":"10.1016\/j.anorl.2023.11.004_bib0540","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1001\/archotol.1981.00790480015004","article-title":"Cisplatin therapy for adenoid cystic carcinoma","volume":"107","author":"Schramm","year":"1981","journal-title":"Arch Otolaryngol"},{"key":"10.1016\/j.anorl.2023.11.004_bib0545","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1002\/hed.10387","article-title":"MUC4 and ERBB2 expression in major and minor salivary gland mucoepidermoid carcinoma","volume":"26","author":"Weed","year":"2004","journal-title":"Head Neck"},{"key":"10.1016\/j.anorl.2023.11.004_bib0550","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1158\/1078-0432.CCR-03-0253","article-title":"HER2 expression in salivary gland carcinomas: dependence on histological subtype","volume":"10","author":"Glisson","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.anorl.2023.11.004_bib0555","doi-asserted-by":"crossref","first-page":"2526","DOI":"10.1002\/cncr.21116","article-title":"Clinical and immunohistologic typing of salivary duct carcinoma: a report of 50 cases","volume":"103","author":"Jaehne","year":"2005","journal-title":"Cancer"},{"key":"10.1016\/j.anorl.2023.11.004_bib0560","first-page":"5675","article-title":"Amplification and overexpression of HER-2\/neu in carcinomas of the salivary gland: correlation with poor prognosis","volume":"54","author":"Press","year":"1994","journal-title":"Cancer Res"},{"key":"10.1016\/j.anorl.2023.11.004_bib0565","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1002\/hed.20614","article-title":"Salivary duct carcinoma: a clinical and histologic review with implications for trastuzumab therapy","volume":"29","author":"Nabili","year":"2007","journal-title":"Head Neck"},{"key":"10.1016\/j.anorl.2023.11.004_bib0570","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1034\/j.1600-0714.2002.00017.x","article-title":"HER2\/neu expression in adenoid cystic carcinoma of salivary gland origin: an immunohistochemical study","volume":"31","author":"Dori","year":"2002","journal-title":"J Oral Pathol Med"},{"key":"10.1016\/j.anorl.2023.11.004_bib0575","doi-asserted-by":"crossref","first-page":"6001","DOI":"10.1200\/JCO.2019.37.15_suppl.6001","article-title":"Ado-trastuzumab emtansine in patients with HER2 amplified salivary gland cancers (SGCs): results from a phase II basket trial","volume":"37","author":"Li","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.anorl.2023.11.004_bib0580","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/S1368-8375(03)00097-6","article-title":"Herceptin in patients with advanced or metastatic salivary gland carcinomas. A phase II study","volume":"39","author":"Haddad","year":"2003","journal-title":"Oral Oncol"},{"key":"10.1016\/j.anorl.2023.11.004_bib0585","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1200\/JCO.18.00545","article-title":"Phase II trial of trastuzumab and docetaxel in patients with human epidermal growth factor receptor 2-positive salivary duct carcinoma","volume":"37","author":"Takahashi","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.anorl.2023.11.004_bib0590","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1002\/hed.20714","article-title":"Successful treatment of pulmonary metastatic salivary ductal carcinoma with trastuzumab-based therapy","volume":"30","author":"Prat","year":"2008","journal-title":"Head Neck"},{"key":"10.1016\/j.anorl.2023.11.004_bib0595","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1017\/S0022215108002314","article-title":"Biological therapy of salivary duct carcinoma","volume":"123","author":"Nashed","year":"2009","journal-title":"J Laryngol Otol"},{"key":"10.1016\/j.anorl.2023.11.004_bib0600","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1007\/s12032-011-9884-1","article-title":"Targeted therapy with trastuzumab for advanced salivary ductal carcinoma: case report and literature review","volume":"29","author":"Kaidar-Person","year":"2012","journal-title":"Med Oncol"},{"key":"10.1016\/j.anorl.2023.11.004_bib0605","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1634\/theoncologist.2012-0369","article-title":"Trastuzumab for the treatment of salivary duct carcinoma","volume":"18","author":"Limaye","year":"2013","journal-title":"Oncologist"},{"key":"10.1016\/j.anorl.2023.11.004_bib0610","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1093\/annonc\/mdz291","article-title":"Ado-trastuzumab emtansine (T-DM1) in patients with HER2-amplified tumors excluding breast and gastric\/gastroesophageal junction (GEJ) adenocarcinomas: results from the NCI-MATCH trial (EAY131) subprotocol Q","volume":"30","author":"Jhaveri","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.anorl.2023.11.004_bib0615","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.oraloncology.2017.06.023","article-title":"Combination of docetaxel, trastuzumab and pertuzumab or treatment with trastuzumab-emtansine for metastatic salivary duct carcinoma","volume":"72","author":"van Boxtel","year":"2017","journal-title":"Oral Oncol"},{"key":"10.1016\/j.anorl.2023.11.004_bib0620","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1093\/annonc\/mdx771","article-title":"A prospective phase II study of combined androgen blockade in patients with androgen receptor-positive metastatic or locally advanced unresectable salivary gland carcinoma","volume":"29","author":"Fushimi","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.anorl.2023.11.004_bib0625","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1002\/hed.25035","article-title":"Androgen deprivation therapy for androgen receptor-positive advanced salivary duct carcinoma: a nationwide case series of 35 patients in The Netherlands","volume":"40","author":"Boon","year":"2018","journal-title":"Head Neck"},{"key":"10.1016\/j.anorl.2023.11.004_bib0630","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.ejca.2018.12.035","article-title":"Adjuvant androgen deprivation therapy for poor-risk, androgen receptor-positive salivary duct carcinoma","volume":"110","author":"van Boxtel","year":"2019","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.anorl.2023.11.004_bib0635","doi-asserted-by":"crossref","first-page":"4061","DOI":"10.1200\/JCO.21.00468","article-title":"Abiraterone acetate in patients with castration-resistant, androgen receptor-expressing salivary gland cancer: a phase II trial","volume":"39","author":"Locati","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.anorl.2023.11.004_bib0640","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1056\/NEJMoa1714448","article-title":"Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children","volume":"378","author":"Drilon","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.anorl.2023.11.004_bib0645","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S1470-2045(19)30691-6","article-title":"Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1\u20132 trials","volume":"21","author":"Doebele","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.anorl.2023.11.004_bib0650","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/S1470-2045(19)30856-3","article-title":"Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1\/2 clinical trials","volume":"21","author":"Hong","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.anorl.2023.11.004_bib0655","doi-asserted-by":"crossref","first-page":"7137","DOI":"10.1158\/0008-5472.CAN-05-1125","article-title":"Mect1-Maml2 fusion oncogene linked to the aberrant activation of cyclic AMP\/CREB regulated genes","volume":"65","author":"Coxon","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/j.anorl.2023.11.004_bib0660","doi-asserted-by":"crossref","first-page":"3869","DOI":"10.1038\/onc.2013.348","article-title":"Aberrantly activated AREG-EGFR signaling is required for the growth and survival of CRTC1-MAML2 fusion-positive mucoepidermoid carcinoma cells","volume":"33","author":"Chen","year":"2014","journal-title":"Oncogene"},{"key":"10.1016\/j.anorl.2023.11.004_bib0665","doi-asserted-by":"crossref","first-page":"6086","DOI":"10.1200\/JCO.2016.34.15_suppl.6086","article-title":"PACSA: phase II study of pazopanib in patients with progressive recurrent or metastatic (R\/M) salivary gland carcinoma (SGC)","volume":"34","author":"Guigay","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.anorl.2023.11.004_bib0670","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1097\/COC.0000000000000429","article-title":"Pembrolizumab for the treatment of advanced salivary gland carcinoma: findings of the phase 1b KEYNOTE-028 study","volume":"41","author":"Cohen","year":"2018","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.anorl.2023.11.004_bib0675","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/JCO.19.02105","article-title":"Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability\/mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 study","volume":"38","author":"Marabelle","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.anorl.2023.11.004_bib0680","doi-asserted-by":"crossref","first-page":"6083","DOI":"10.1200\/JCO.2019.37.15_suppl.6083","article-title":"NISCAHN: a phase II, multicenter nonrandomized trial aiming at evaluating nivolumab (N) in two cohorts of patients (pts) with recurrent\/metastatic (R\/M) salivary gland carcinoma of the head and neck (SGCHN), on behalf of the Unicancer Head & Neck Group","volume":"37","author":"Fayette","year":"2019","journal-title":"JCO"},{"key":"10.1016\/j.anorl.2023.11.004_bib0685","doi-asserted-by":"crossref","first-page":"6002","DOI":"10.1200\/JCO.2021.39.15_suppl.6002","article-title":"A phase II trial cohort of nivolumab plus ipilimumab in patients (Pts) with recurrent\/metastatic salivary gland cancers (R\/M SGCs)","volume":"39","author":"Burman","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.anorl.2023.11.004_bib0690","doi-asserted-by":"crossref","first-page":"3972","DOI":"10.1002\/cncr.33036","article-title":"Tipifarnib in recurrent, metastatic HRAS-mutant salivary gland cancer","volume":"126","author":"Hanna","year":"2020","journal-title":"Cancer"}],"container-title":["European Annals of Otorhinolaryngology, Head and Neck Diseases"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879729623001564?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879729623001564?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T01:54:30Z","timestamp":1756691670000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1879729623001564"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":69,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["S1879729623001564"],"URL":"https:\/\/doi.org\/10.1016\/j.anorl.2023.11.004","relation":{},"ISSN":["1879-7296"],"issn-type":[{"value":"1879-7296","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Systemic therapies for salivary gland carcinoma (excluding adenoid cystic carcinoma): REFCOR recommendations by the formal consensus method","name":"articletitle","label":"Article Title"},{"value":"European Annals of Otorhinolaryngology, Head and Neck Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.anorl.2023.11.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Masson SAS.","name":"copyright","label":"Copyright"}]}}